Track JSPR and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Jasper Therapeutics Inc
2200 Bridge Pkwy, Redwood City, CA, United States, 94065
IPO
2021
Employees
22
Industry
Biotechnology
Sector
Healthcare
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20250+4
4
Analyst Ratings
4 analysts covering
Buy100%recommend buy
Buy
4
Hold
0
Sell
0